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ABSTRACT: Coibamide A (CbA) is a marine natural product
with potent antiproliferative activity against human cancer cells and
a unique selectivity profile. Despite promising antitumor activity,
the mechanism of cytotoxicity and specific cellular target of CbA
remain unknown. Here, we develop an optimized synthetic CbA
photoaffinity probe (photo-CbA) and use it to demonstrate that
CbA directly targets the Sec61α subunit of the Sec61 protein
translocon. CbA binding to Sec61 results in broad substrate-
nonselective inhibition of ER protein import and potent
cytotoxicity against specific cancer cell lines. CbA targets a lumenal
cavity of Sec61 that is partially shared with known Sec61 inhibitors,
yet profiling against resistance conferring Sec61α mutations
identified from human HCT116 cells suggests a distinct binding
mode for CbA. Specifically, despite conferring strong resistance to all previously known Sec61 inhibitors, the Sec61α mutant R66I
remains sensitive to CbA. A further unbiased screen for Sec61α resistance mutations identified the CbA-resistant mutation S71P,
which confirms nonidentical binding sites for CbA and apratoxin A and supports the susceptibility of the Sec61 plug region for
channel inhibition. Remarkably, CbA, apratoxin A, and ipomoeassin F do not display comparable patterns of potency and selectivity
in the NCI60 panel of human cancer cell lines. Our work connecting CbA activity with selective prevention of secretory and
membrane protein biogenesis by inhibition of Sec61 opens up possibilities for developing new Sec61 inhibitors with improved drug-
like properties that are based on the coibamide pharmacophore.
■ INTRODUCTION
Natural products are a rich source of bioactive and specific
chemical probes and serve as starting points for development
of new therapeutics once their mechanism of action and
cellular targets have been identified.1,2 Coibamide A (CbA)3 is
an N-methyl-stabilized lariat depsipeptide (Figure 1) isolated
from a Caldora species4 of marine cyanobacterium collected in
Panama. CbA potently inhibits cell proliferation, migration,
and invasive capacity, and in early assessments of the in vivo
activity of the natural product, or simplified analogue, inhibited
tumor growth in subcutaneous xenograft models of human
glioblastoma and breast cancer.5,6 Further, CbA rapidly
induces a macroautophagy stress response in mammalian
cells, and a phase-specific G1 cell-cycle block prior to cell
death.5,7 The observed biological profile and distinct pattern of
selectivity against cell lines of the National Cancer Institute
(NCI) 60 human tumor cell line panel has generated
considerable interest in CbA, resulting in development of
total synthesis methods and revision of the absolute
configuration of the natural product.8−10
CbA inhibits expression of the integral membrane receptor,
vascular endothelial growth factor receptor 2 (VEGFR-2), and
its secreted ligand vascular endothelial growth factor A
(VEGF-A). It induces mTOR-independent autophagy in a
manner similar to apratoxin A (AprA), a previously
characterized inhibitor of protein import into the early
secretory pathway,5 despite yielding different cytotoxic profiles
against cell lines of the NCI-60 tumor cell line panel.3,11
Protein secretion is a complicated multistep process12 that
begins when nascent secretory proteins are synthesized in the
cytosol. Small molecule probes with a defined mechanism have
allowed dissection of the basic function of the secretory
pathway13 and provided new insights into the mechanism of
protein transport into the endoplasmic reticulum.14−17 Such
Received: April 24, 2020
Accepted: July 1, 2020
Published: July 1, 2020
Articlespubs.acs.org/acschemicalbiology
© 2020 American Chemical Society
2125
https://dx.doi.org/10.1021/acschembio.0c00325
ACS Chem. Biol. 2020, 15, 2125−2136
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,
provided the author and source are cited.
D
ow
nl
oa
de
d 
vi
a 
U
N
IV
 O
F 
H
EL
SI
N
K
I o
n 
Se
pt
em
be
r 2
1,
 2
02
0 
at
 0
7:
30
:3
1 
(U
TC
).
Se
e 
ht
tp
s:/
/p
ub
s.a
cs
.o
rg
/sh
ar
in
gg
ui
de
lin
es
 fo
r o
pt
io
ns
 o
n 
ho
w
 to
 le
gi
tim
at
el
y 
sh
ar
e 
pu
bl
ish
ed
 a
rti
cl
es
.
probes can also serve as therapeutic lead scaffolds for targeting
diseases where the secretory pathway plays a central role.18
The first step in protein secretion is entry into the endoplasmic
reticulum (ER), after which newly synthesized secretory
polypeptides undergo distinct maturation steps that enable
correctly folded proteins to exit the ER and be targeted to their
correct final destinations. Previously reported natural products
that prevent protein entry into the secretory pathway include,
in addition to AprA,14 HUN-7293 (pestahivin)19,20 and related
synthetic cotransins,19−21 mycolactone A/B,15,22,23 decatran-
sin,16 ipomoeassin F (IpoF),24 and eeyarestatin I com-
pounds.25 However, the critical step inhibited by CbA during
biogenesis of VEGFR-2 and VEGF-A and the direct cellular
target of CbA remain unknown.
In the current study, we explore the structure−activity
relationship (SAR) of CbA to develop an optimized CbA
photoaffinity probe (photo-CbA), which allowed us to identify
the Sec61α subunit of the Sec61 protein translocation channel
as the direct cellular binding target of CbA. Sec61 binding
prevents cellular production of a broad range of secreted and
integral membrane proteins that depend on Sec61 for their
cotranslational biogenesis. The CbA binding site on Sec61α
near the lumenal plug domain seems to be only partially
overlapping to that of previously described substrate-non-
selective Sec61 inhibitors AprA and mycolactone, suggesting
Figure 1. Cytotoxicity of synthetic and Pra-containing coibamides.
(A) Structure of CbA. (B) Human MDA-MB-231 breast cancer cells
were treated with increasing concentrations of synthetic CbA or
vehicle (0.1% DMSO) and cell viability assessed at 72 h by an MTS
end-point assay. (C) Structure of Photo-CbA. (D) Human HCT116
cells were treated with increasing concentrations of synthetic or
photo-CbA in 0.1% DMSO, and cell viability assessed at 72 h by
Alamar Blue assay.
Figure 2. Photo-cross-linking of photo-CbA to Sec61α and CbA stabilization of Sec61 in cells. Photocotransin (CT7) or photocoibamide (pCbA)
cross-linking to cells or sheep rough microsomes (SRM). Samples were photolyzed and the covalent adduct detected by click-chemistry to
TAMRA-azide reporter and in-gel fluorescence scanning and Western blotting. (A) A431 cell lines were first incubated with CbA or carrier,
followed by incubation with photo-CbA, photolysis, and click chemistry. Following SDS PAGE, lysates were queried for in gel fluorescence and
subsequently transferred for anti-Sec61α and anti-FLAG Western Blot. Arrows indicate Sec61 (with or without a 10 kDa insert), star indicates
nonspecific WB signal, triangle indicates free TAMRA dye within the gel. (B) As in A but in SRMs. Sample without UV irradiation shows the
nonspecific background labeling of photo-CbA. (C) SRMs were first incubated with indicated concentrations of AprA, or Myco, followed by
incubation with photo-CbA, photolysis, and click chemistry. (D) CT7 cross-linking to microsomes in the presence or absence of 10 μM CbA. (E)
Stabilization of intracellular Sec61α by CbA. Isothermal concentration−response analysis of Sec61α in the presence or absence of CbA (0.01 nM to
3 μM), OSU-03012 (0.03 nM to 10 μM), or 0.1% DMSO. Intact U87-MG glioblastoma cells were treated as indicated and subjected to heating at
51 °C for 3 min. Heat-treated cell suspensions were snap frozen, lysates cleared by centrifugation, and the soluble fraction analyzed by SDS-PAGE
and Western blotting. Note that Sec61α migrated above the 40 kDa molecular weight marker in several human cell lines using a standard Western
blot protocol (Abcam ab183046; Figure S26C). (F) Quantification of immunoblot data shown in E. Sec61α band intensity was normalized to
tubulin, and data points were fitted using nonlinear regression analysis.
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that CbA interacts with Sec61 through unique interactions.
CbA also has differential growth inhibitory potential against a
panel of cancer cells relative to AprA and IpoF.
■ RESULTS AND DISCUSSION
Synthesis of CbA and Its Photoaffinity Derivatization.
Obtaining sufficient quantities of CbA for detailed mechanism
of action studies from field-collected material is highly
challenging,3 and thus we first set out to establish a total
synthesis for this N-methylated peptidic macrocycle (Figure
1A) using a modification of a previously reported method8
(see the Supporting Information). Briefly, we initially
constructed the middle part of CbA (MeThr5−MeIle7:
fragment 2) on (2-Cl)Trt resin by standard Fmoc-solid
phase peptide synthesis, and then conjugated the N-terminal
four residues (Me2Val1−MeLeu4: fragment 1). After coupling
of D-MeAla11 onto the Thr5 hydroxy group, the remaining
sequence (Ala8−Tyr(Me)10: fragment 3) was appended.
EDCI/HOAt-mediated cyclization of the open-chain precur-
sor, which was obtained by cleavage from the resin by
treatment with HFIP, afforded the expected CbA.8 Having a
robust source of synthetic CbA, we proceeded with biological
characterization of the synthetic product in human MDA-MB-
231 triple negative breast cancer cells. These cells were
previously identified as highly sensitive (IC50 = 2.8 nM) to
natural CbA,3 and we observed consistent cytotoxic potency
(IC50 = 1.6 nM) for the synthetic CbA (Figure 1B).
Similar to the previously reported photocotransin,26 we
aimed to install a diazirine group in CbA for photoactivated
cross-linking to the binding target and an alkyne handle for in
situ click chemistry coupling to fluorescent or affinity tags. All-
L-CbA was reported to have moderate micromolar cytotoxicity
against three cancer cell lines,27 while [D-MeAla11]-all-L-CbA
displayed high nanomolar activity against four cancer cell
lines.9 Given the adverse effect of the L-MeAla11 configuration
for CbA activity, we anticipated that the neighboring
Tyr(Me)10 could be involved in target interactions and
could be substituted with the nearly isosteric 4-[3-(trifluor-
omethyl)-3H-diazirin-3-yl]phenylalanine (Tdf) side chain.
This substitution is further supported by the loss of activity
for an AprA analogue in which the MeTyr is epimerized.28
Positioning of the clickable alkyne amino acid was informed
by a structure−activity relationship study to identify the
optimal position for insertion of a propargylglycine (Pra)
residue. In total, we synthesized six Pra/MePra-containing
CbA analogues using the identical protocol with on-resin
fragment condensation. Comparative antiproliferative testing
in A549 lung cancer cells led to selection of residue position 3
for MePra in the targeted photoprobe (Figure S1). Dual
modifications with MePra3 and Tdf10 afforded a potent
photoaffinity probe, photocoibamide (Photo-CbA) with an
alkyne handle (IC50 = 6.5 nM against HCT116 cells; Figure
1D).
Photo-CbA Directly Targets the Sec61α Subunit of
the Protein Translocon. To identify the direct photo-CbA
photo-cross-linking partner in an unbiased manner, we
incubated live human A431 carcinoma cells with photo-CbA
either in the presence or in the absence of parent CbA,
followed by photolysis in intact cells. Detection of photo-cross-
linked adducts was then carried out following installation of a
TAMRA fluorophore by Cu(I) catalyzed Click chemistry
under denaturing conditions and in-gel fluorescence scanning.
This revealed a single cross-linked band of approximately 37
kDa in molecular weight, which was efficiently competed by
addition of excess unmodified CbA (Figure 2A, first 2 lanes). A
prior observation that CbA prevents biogenesis and ER import
of VEGFR-2 during or following protein translation5 suggests
that CbA may target a component of the ER protein biogenesis
machinery. The observed 37 kDa molecular weight corre-
sponds to that of the Sec61α subunit, which is the essential
subunit of the protein translocon that forms the conduit
through which newly synthesized proteins enter the secretory
pathway.12 As Sec61α is the direct target of established highly
selective natural products that inhibit ER import such as
cotransins, AprA, decatransin, and mycolactone,29 we specu-
lated that CbA could prevent VEGFR-2 expression by directly
inhibiting Sec61. Repeating the photo-cross-linking assay
against cells in which the endogenous locus of Sec61α has
been edited to introduce additional sequence bearing a
3xFLAG epitope that increases the molecular weight by
approximately 10 kDa revealed that the photo-cross-linked
product shifted size accordingly (Figure 2A, last 2 lanes). As
further validation that photo-CbA is cross-linking to Sec61α, a
nonglycosylated protein, we used endoglycosidase H treatment
to strip glycans from proteins in our sample. While the
abundant and glycosylated Sec61 translocon component,
Translocation Associated Membrane Protein 1 (TRAM),
shifted to a smaller molecular weight species, the photo-
cross-linked product remained at approximately 37 kDa,
indicating that the target of photo-CbA is a non glycosylated
protein (Figure S26).
To compare the binding of photo-CbA to known inhibitors
of Sec61α, we then investigated cross-linking of photo-CbA
and CT7, a potent and specific photoaffinity inhibitor of
Sec61α,26 in isolated ER microsomes. Incubation with photo-
CbA yielded a single band of approximately 37 kDa apparent
molecular weight as per the in vivo result, which could be
competed out in a concentration dependent manner by the
addition of excess unmodified CbA (Figure 2B). We then
tested whether photo-CbA cross-linking can be competed with
known Sec61 ligands, AprA or mycolactone.14,15,28 Both
compounds prevented photo-CbA cross-linking in a concen-
tration-dependent manner; similarly, addition of excess CbA
competed for cross-linking by cotransin CT7, both consistent
with the notion that the photo-CbA cross-linked adduct is with
Sec61α (Figure 2C and D)
We next used cellular thermal shift assays as an independent
test of the ability of CbA to engage with Sec61 in cells. The
feasibility of this approach was first interrogated by establishing
a melting curve for Sec61α by analysis of soluble protein
fractions by Western blot following a heat challenge (Figure
S26). For these studies, intact human U87-MG glioblastoma
cells were subjected to temperatures ranging from 45 to 72 °C
in the presence and absence of CbA, AprA, or an unrelated
PDK-1 and putative immunoglobulin binding protein (BiP)
inhibitor, OSU-03012. Both CbA and AprA stabilized Sec61α,
resulting in the continued detection of the presumed ligand-
bound protein at a higher temperature range (60−66 °C) than
for the relatively weak immunoreactivity observed for either
vehicle- or OSU-03012-treated samples (Figure S26). On the
basis of these results, a fixed temperature (51 °C) was then
selected for isothermal dose−response fingerprinting of
Sec61α in the presence, or absence, of increasing concen-
trations of CbA (0.01 nM to 3 μM) or OSU-03012 (0.03 nM
to 10 μM). Under these conditions, CbA stabilized Sec61α in a
concentration-dependent manner with half-maximal stabiliza-
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tion observed at ∼0.2 nM concentration, whereas no apparent
stabilization of Sec61α was observed with OSU-03012 (Figure
2E and F).
Collectively, these data provide robust evidence indicating
that CbA directly and specifically interacts with the Sec61α
subunit of the ER protein translocation channel. All currently
known natural product inhibitors of Sec61 bind at the same
lumenal Sec61 cavity,29 and our photo-cross-linking data
(Figure 2) suggests that also CbA binds Sec61α at this or a
partially overlapping region.
Coibamide Reversibly Inhibits Biogenesis of Secreted
and Membrane Proteins. The Sec61 translocon facilitates a
key step in protein maturation by mediating the insertion of
substrate proteins into the ER membrane or across it into the
lumenal space.12 To investigate the global impact of CbA on
cellular protein biogenesis, we performed metabolic labeling
with 35S-methionine/cysteine in HCT116 colon carcinoma
cells and investigated the processing of newly synthesized
proteins in the presence or absence of CbA. In these
experiments, even micromolar CbA concentrations did not
result in reduction of the production levels of total cellular
proteins (Figure 3A). However, production of glycosylated and
secreted proteins was severely inhibited by CbA in a
concentration-dependent manner, and full inhibition was
observed with 100 nM CbA (Figure 3B and C). Collectively,
CbA treatment does not impact cellular protein synthesis but
instead prevents cotranslational protein glycosylation and net
nascent protein secretion, which both require function of the
Sec61 translocon. In this experiment, the effect of CbA on
nascent protein synthesis was similar to that of AprA, a
Figure 3. CbA specifically inhibits biogenesis of secretory and membrane proteins. (A to C) HCT-116 cells were labeled with 35S-Met and 35S-Cys
in the presence of increasing concentrations of CbA. CHX/CA denotes control samples treated with cycloheximide and chloramphenicol to inhibit
protein synthesis by cytosolic and mitochondrial ribosomes. Molecular weights are shown in kDa. (A) The collected cells were homogenized and
analyzed by SDS-PAGE and autoradiography. (B) As in A but the samples are glycosylated protein fractions isolated with ConA-lectin affinity. (C)
As in A but the samples are TCA-precipitated culture medium from the same experiment. (D) HEK-293T cells transiently expressing human
VCAM1 were treated with 3 nM CbA, AprA, or vehicle (0.1% DMSO) at 5 h post-transfection and protein expression analyzed by Western
Blotting at 24 h. (E) As in D, cells were treated with CbA (3 nM) or vehicle (0.1% DMSO) at 5 h post-transfection, incubated for a further 24 h,
after which CbA was diluted 6-fold by the addition of fresh medium before the cells were harvested at the indicated time points. In D and E, the
arrow indicates mature VCAM1 in several glycosylation states; the star denotes PARP-1.
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previously described substrate-nonselective inhibitor of ER
protein translocation.14
We next set out to investigate the effects of CbA on the
biogenesis of type I integral membrane proteins using human
vascular cell adhesion molecule 1 (VCAM1) as a model
protein. Biogenesis of this protein is potently inhibited by
cotransin, a highly substrate-selective inhibitor of VCAM1
membrane insertion.19,20 We transiently expressed human
VCAM1 in HEK293T cells and treated the cells with either
CbA (3 nM), AprA (3 nM), or vehicle (0.1% DMSO) for 24 h.
Immunoblot analysis of whole-cell lysates harvested after
compound treatment revealed a strong reduction in VCAM1
expression in cells treated with either CbA or AprA (Figure
3D). Importantly, we did not observe evidence of proteolytic
processing of poly[ADP-ribose] polymerase 1 (PARP-1),
suggesting that caspase-dependent cell death is not involved
in inhibition of VCAM1 expression. Further, dilution of CbA
to subnanomolar concentrations, by the addition of fresh
culture medium, resulted in a time-dependent reversal of
VCAM1 expression inhibition, demonstrating that CbA
inhibits Sec61-mediated protein biogenesis in a reversible
manner (Figure 3E).
Coibamide Inhibits Sec61-Mediated Translocation in
a Substrate-Nonselective Manner. Earlier studies have
revealed that cotransin downregulates VCAM1 by preventing
its Sec61-mediated ER insertion and causing the cytosolic
displacement of the nascent VCAM1 polypeptide and
subsequent cytosolic degradation by the ubiquitin proteasome
system.20 Thus, we set out to test whether CbA inhibits
VCAM1 expression via a similar mechanism. Here, treating
cells with CbA resulted in downregulation of VCAM1
expression, which was rescued in a time-dependent manner
by treatment with bortezomib (BtZ), a specific inhibitor of the
proteasome (Figure 4A). Therefore, CbA appears to inhibit
VCAM1 expression during or after nascent VCAM1 synthesis,
which could involve stages of ER targeting, membrane
insertion, maturation, or protein trafficking. The observed
accumulation of immature unglycosylated VCAM1 forms
following CbA and BtZ treatment indicate that CbA interferes
with proper VCAM1 maturation (Figure 4A).
Figure 4. CbA inhibits translocation of a range of Sec61 substrates. (A and B) The star indicates the unprocessed form of the protein, and the
arrow points to the processed, mature form. Molecular weights of the standards are shown in kDa. (A) Cells transiently expressing VCAM1 were
treated 5 h post-transfection with either 1 or 3 nM CbA in the presence or absence of 20 nM proteasomal inhibitor bortezomib (BtZ). Whole cell
lysates were analyzed by Western Blotting after 24 h. (B and C) For the in vitro translocation assay (IVT), the indicated proteins were translated in
the presence of microsomes, 35S-Met, and the indicated inhibitors. (B) Translocation of glycosylated proteins was assessed by change in migration
in SDS-PAGE. Endoglycosidase treatment (EndoH) was used to demonstrate that the altered migration was due to glycosylation. Yeast α-factor,
mouse elongation of very long chain fatty acids protein 3 (CIG30), beta-lactamase (β-Lac). (C) Translocation of nonglycosylated proteins was
demonstrated by treatment with proteinase K (PK). The Hamster binding immunoglobulin protein (BiP) and bovine prolactin (Prl). The star
indicates protein degradation products following PK digestion, and the arrow points to the intact protein.
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To dissect the biochemical mechanism by which CbA
prevents maturation of nascent secretory proteins, we used a
reconstituted mammalian translation system supplemented
with isolated sheep rough microsomes (SRM).30 In these
experiments, CbA did not influence protein translation of any
of the diverse Sec61 substrate proteins tested, which included
Figure 5. CbA mode of inhibition is specific compared to known Sec61 inhibitors. (A) Cell viability was measured by Alamar Blue assay (mean ±
SD, n = 4, all cell lines assayed simultaneously) for HCT-116 cell lines isolated on the basis of CbA resistance in the presence of concentration
series of indicated compounds. (B) Cell viability was measured by Alamar Blue assay (mean ± SD, n = 4, all cell lines assayed simultaneously) for
HEK293FRT cells stably expressing Sec61α mutants in the presence of concentration series of indicated compounds. (C) Comparison of published
NCI60 data for CbA,3 AprA,11 and IpoF.33 The heat map was derived by plotting each GI50 value divided by the median GI50 for that compound. X
indicates a cell line that was not tested. Closed arrowhead indicates cell lines with most notable differences across the three compounds.
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secreted proteins (yeast α-factor, β-lactamase, BiP, prepro-
lactin) and a polytopic membrane protein (CIG30). We
assayed the inhibitory effect of CbA on protein processing in
vitro and compared the effects with those of AprA and
cotransin analogue CT8 (Figure 4 B). CbA prevents both
glycosylation (yeast α-factor) and signal peptide cleavage (β-
lactamase). Processing of secreted proteins was inhibited, while
CIG30, a multipass membrane protein, was resistant against
CbA and all other translocation inhibitors tested (CT8, AprA)
and is also known to be resistant toward mycolactone,15
consistent with the critical CIG30 dependence for the ER
membrane protein complex (EMC) instead of Sec61 for its
biogenesis31
To further investigate the CbA-sensitive stage of protein
translocation, we again used the reconstituted in vitro
translation and translocation system and queried the
accessibility of Sec61 substrate proteins to exogenous
proteinase K (PK) in the presence or absence of SRM. In
these reactions, nascent polypeptides of ER translocated BiP
and preprolactin (Prl) are shielded from protease digestion in
the presence of SRM, yet are cleaved in the absence of SRM or
when microsomes are solubilized with detergent indicative of
membrane translocation (Figure 4C). However, the addition
of 1 μM CbA, CT8, or AprA into SRM-containing reactions
renders the nascent polypeptides sensitive to PK (Figure 4C),
indicating that these compounds prevent ER entry of the newly
synthesized proteins. Collectively, our data (Figures 3D, 4)
indicate that CbA potently prevents ER insertion and
subsequent processing of a wide range of secreted and integral
membrane proteins with the notable exception of membrane
proteins with N-terminal transmembrane segments of the type
III topology.
Coibamide Binding to Sec61 Is Distinct from Other
Translocation Inhibitors. In an effort to map the location of
the CbA binding site on Sec61α, we used a genetic selection
approach in mammalian cells and attempted to identify specific
resistance-conferring point mutations. Such chemogenetic
screens are a powerful means to discover novel mutations
and mechanisms of action for cell-active small molecules and
have been used to identify point mutations in SEC61A1 that
confer specific resistance to cytotoxicity of different Sec61
inhibitors.14,16,17,32 We exposed EMS mutagenized HCT116
colon carcinoma cells to 50−100 nM CbA (IC50 ∼ 29 nM),
which resulted in a majority of the cells dying, yet during
selection, six colonies grew and were isolated. Monoclonal cell
lines derived from the colonies exhibited strong resistance to
CbA (up to 100-fold desensitization) and to an even greater
degree to AprA (Figure 5A). Sequencing the coding regions of
the SEC61A1 gene revealed a single nucleotide transition
encoding for the heterozygous Sec61α mutation S71P. In
contrast to CbA selection, previous unbiased resistance
mapping screens in HCT116 cells with cotransin, AprA, and
dectransin all revealed a range of Sec61α mutations conferring
specific resistance to the tested Sec61 inhibitors. To assay the
effect of previously identified Sec61α mutations, we tested a
panel of mutations in naive HEK293 FRT cells where the
Figure 6. Structure of Sec61 complex and location of resistance point mutations. Lateral and ER lumenal views in closed and open conformations
of the Sec61 complex are shown. Lateral gate helices 2 + 3 (light blue) and 7 + 8 (light coral) as well as the plug region (light green) are indicated
on the Sec61α core subunit (light gray). Mutations in Sec61α at residues 82 and 86 in helix 2 are shown in purple, lumenal plug residues 66 and 71
are shown in teal. The open but stalled Sec61 complex is shown with bound preprolactin signal sequence (brown). Structural coordinates were
obtained from the Protein Data Bank, IDs 3J7Q and 3JC2.
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mutant Sec61α proteins are stably expressed from an
exogenous locus at a similar level as endogenous Sec61α.17
As we reported earlier, all of the tested mutations conferred
strong resistance to AprA,14 but only moderate resistance was
observed for CbA (Figure 5B). This finding is surprising
especially for the R66I mutation that confers essentially
complete resistance for all known Sec61 inhibitors,14−16,24 yet
only causes moderate (∼7-fold) desensitization to CbA
(Figure 5B). The Sec61α mutations S82P and T86M that
confer resistance to other Sec61 inhibitors, but not CbA, are
clustered on the lumenal end of the Sec61 lateral gate, whereas
mutations R66I and S71P are located in different parts of the
Sec61 plug domain (Figure 6). Taken together, these
mutational results suggest that CbA may interact with Sec61
in a unique manner or possibly bind a different conformation
of the channel.
■ SUMMARY
Here, we report the comprehensive identification of target
interactions of coibamide A (CbA), a cytotoxic marine natural
product, with the ability to inhibit biogenesis of secreted and
integral membrane proteins. By developing an isosteric
photoaffinity probe of CbA, we demonstrate that the main
binding target of CbA in mammalian cells is the Sec61α
subunit of the Sec61 protein translocon complex. Metabolic
labeling experiments in cells and biochemical ER translocation
experiments indicate that CbA inhibits cotranslational Sec61-
facilitated ER translocation in a substrate-nonselective manner.
Finally, through an unbiased mutational mapping approach, we
demonstrate that the cytotoxic potential of CbA for
mammalian cells results from Sec61 inhibition, likely through
binding of a Sec61 site partially overlapping with other
substrate-selective and nonselective Sec61 inhibitors.
The Sec61 translocon forms a membrane channel which
facilitates the essential ER membrane translocation or
membrane integration step during biogenesis of secretory or
integral membrane proteins, respectively. As rapidly proliferat-
ing cancer cells display heightened dependence on protein
synthesis, pharmacological targeting of cellular proteostatic
pathways, including the ER protein biogenesis machinery, has
potential for the development of new therapeutic strategies,34
prompting an interest in finding new privileged scaffolds to
target critical proteostasis factors. Recent work has identified
many structurally distinct natural product small molecules that
appear to have evolved independently in distinct micro-
organisms to target Sec61 as a way to modulate or prevent
biogenesis of secreted or integral membrane proteins.
Intriguingly, all of these inhibitors appear to target Sec61 at
its lumenal cavity near the Sec61 lateral gate and plug domains
(Figure 6) whether they inhibit production of Sec61 substrate
proteins in a substrate-selective (cotransins)19,20 or substrate-
nonselective (AprA, mycolactone, IpoF, decatransin)14−16,22,24
manner.
The lumenal Sec61 cavity where all reported inhibitors bind
has been outlined by mutations identified in several
independent studies in both mammalian and yeast chemo-
genomic screens (reviewed in ref 29). Together the mutations
outline a general binding pocket at the lumenal end of the
Sec61α subunit, which appears to be at least partially shared by
all five published inhibitors. Yet, a distinct pattern of resistance
has been observed for some of these inhibitors,14,24 suggesting
that despite occupying the same general binding cavity, they
utilize different specific interactions with Sec61 or bind
different conformations of the inherently dynamic channel.
Specifically, Sec61α mutations R66I and S82P confer potent
resistance to all other known Sec61 inhibitors, while only
conferring mild resistance to CbA. This suggests that CbA may
bind Sec61 in a unique way, possibly by targeting a
conformation in which the plug has moved to a different
position. This notion is also supported by failure of our
unbiased screen to identify common Sec61α mutations, which
have been identified for several inhibitors earlier in multiple
resistance mutation screens.14,16,17,24 Future structural studies
will be required to definitively characterize the binding modes
of Coibamide A and other Sec61 inhibitors and can provide a
basis for understanding means for inhibiting Sec61 in a
substrate-selective manner.
This study and earlier work reveal an expansion of the
binding site for Sec61 inhibition by diverse natural and
synthetic inhibitors and prompt the question whether the
observed binding differences translate to different cellular
phenotypes. So far only two inhibitor classes, cotransins and
CADA, have been reported to inhibit biogenesis of Sec61
client proteins with substrate selectivity. All the other reported
natural product inhibitors prevent biogenesis of nearly all
Sec61 dependent secreted and membrane proteins. Preventing
synthesis of key proteins required for cancer cell survival and
proliferation forms the basis for targeting cancer cells with
substrate-selective Sec61 inhibitors.29,36
Also, the substrate-nonselective inhibitors AprA and
coibamide A have demonstrated a therapeutic possibility to
target cancer cells in in vivo models of human cancer,5,28,33,37
albeit with a limited therapeutic window. It remains unclear
how structurally different Sec61 inhibitors with a seemingly
identical biochemical inhibition mechanism could be leveraged
for the design of cell type selective therapeutic lead scaffolds.
To investigate this, we examined the published comparative
growth inhibitory phenotypes across the cell lines assayed in
the USA National Cancer Institute panel of 60 cancer cell lines
(NCI-60)38 against CbA,3 AprA,11 and IpoF.39 This correlative
analysis revealed that each of the three compounds was
designated as “COMPARE-negative,” suggestive of having
distinct cytotoxic mechanisms. While not all data from the two
testing events for each compound were available, there were
activity data from one test event for at least 55 cell lines in each
case, out of a total of 61 different cell lines tested across the
three compounds. Because all three compounds appear to
cause cytotoxicity by targeting the same site on Sec61 in a
substrate-nonselective manner, it is remarkable that the NCI-
60 panel fails to recognize them as a mechanistic set.
Comparison of the relative sensitivities of the tested cell
lines reveals notable examples of differential cell targeting
despite a lack of common trends at the level of histological cell
types (Figure 5C). For example, the SF268 CNS cancer cell
line ranks in the top 10 most sensitive to CbA (GI50 1.5 nM),
yet it is in the 10 least sensitive cell lines to AprA (GI5051 nM)
and is also less sensitive to IpoF (GI50120 nM). Further, HCC-
2998 colon cancer cells are highly sensitive to CbA (GI50 < 1
nM) and AprA (GI50 3.7 nM), yet they are one of the most
resistant of the cell lines exposed to IpoF (GI50 > 1000 nM).
Finally, the renal cell line TK-10 appears to be much more
sensitive to AprA and IpoF over CbA. Collectively, the NCI-60
profiling data reveal surprising cell type selectivity for these
three compounds that induce cytotoxicity through binding and
global inhibition of ER protein import. Possible explanations
for the observed differences in cell type specificities include
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differences in compound bioavailability, differential cell export
by diverse multidrug efflux pumps, and differences in the
cellular Sec61 inhibition mechanism by the ability to, for
example, target specific Sec61 cofactor complexes. Together,
these findings support the notion that structurally distinct
Sec61 binding inhibitors could be developed to target specific
diseased cells and tissues. In support of this notion, changes in
the structure of AprA and CbA have yielded compound
variants with reduced general cytotoxicity, while retaining
efficacy in human tumor xenograft models.7,33,40 Further,
modifications to the structure of mycolactone demonstrated
that its cytotoxic and anti-inflammatory effects can at least
partially be dissociated from each other.41 Finally, modifica-
tions to the side-chains of the substrate-selective Sec61
inhibitor cotransin altered the range of inhibited Sec61
substrates.21
Taken together, our work adds the structurally distinct cyclic
peptide CbA to the class of potent Sec61 inhibitors whose on-
target interactions at the Sec61α lateral plug region prevent
biogenesis of secreted protein factors and integral membrane
proteins. Our work expands the class of structurally unique
chemotypes that inhibit Sec61 and permit targeting of distinct
cell types, which could be particularly relevant in diseases such
as cancer, inflammation, and certain viral diseases, where
Sec61-facilitated protein biogenesis contributes to disease
progression. Finally, convergent evolution that resulted in the
appearance of multiple classes of inhibitors presumably
targeting diverse eukaryotic Sec61 channel orthologs highlights
the important role that modulating protein biogenesis of
extracellular proteins has for diverse microbial cells in distinct
ecological niches.
■ METHODS
General Method for Synthetic Coibamide Compounds. 1H
NMR spectra were recorded using a JEOL ECA-500 spectrometer.
Chemical shifts are reported in δ (ppm) relative to Me4Si (in CDCl3)
as an internal standard. 13C NMR spectra were recorded using a JEOL
ECA-500 spectrometer and referenced to the residual solvent signal
(δ 77.00 ppm). High resolution mass spectra (HRMS) were recorded
on a Shimadzu LC-ESI-IT-TOF-MS instrument. Optical rotations
were measured using a JASCO P-1020 polarimeter. For flash
chromatography, Wakogel C-200E (Wako) was employed. For
analytical HPLC, a Cosmosil 5C18-ARII column (4.6 × 250 mm,
Nacalai Tesque, Inc.) was employed with a linear gradient of CH3CN
(with 0.1% (v/v) TFA) in H2O at a flow rate of 1 mL/min, and
eluting products were detected by UV at 220 nm. Preparative HPLC
was performed using a Cosmosil 5C18-ARII preparative column (20
× 250 mm, Nacalai Tesque, Inc.) at a flow rate of 8 mL/min.
Reagents for Chemical Biology. The production and
purification of translocation inhibitors have been described
previously: CT7 and CT8,26 AprA,42 and mycolactone.15 OSU-
03012 (AR12) was purchased from Millipore-Sigma. Sheep rough
microsomes were isolated as previously described.43
DNA Constructs and Transfections. DNA constructs encoding
in vitro transcription templates for the cell-free translocation assays
were PCR amplified using 5′-primers containing either T7 or SP6
promoter, a Kozak sequence, and a region complementary to the 5′-
end of the gene. The 3′-primers contained a stop-codon and a region
complementary to the 3′-end of the gene. For analysis of VCAM1
expression, full length VCAM1 in pCDNA3.120 was transiently
expressed in HEK293T cells using jetPRIME Transfection Reagent
(Polyplus transfection) 5 h before treatment.
SDS-PAGE, Autoradiography, and Western Blot. SDS-PAGE
was performed either with Tris/Tricine or with TGX stain-free
polyacrylamide gels (Bio-Rad). For autoradiography, the dried gels
were exposed to a storage phosphor screen (GE Healthcare) and
imaged on a Typhoon phosphorimager (GE Healthcare). For
Western blotting, proteins were transferred to nitrocellulose
membranes (Bio-Rad). Following blocking of the membranes with
Odyssey Blocking Buffer (PBS; LI-COR Biosciences) or 5% (w/v)
nonfat dry milk in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl (TBS)
plus 0.1% Tween-20 (TBS-Tween), the membranes were first
incubated with the appropriate primary antibodies and then with
the appropriate secondary antibodies and finally imaged on an
Odyssey infrared fluorescent scanner (LI-COR Biosciences) or a
MyECL image analysis system (Thermo Fisher Scientific). All
antibodies were from commercial sources and used according to the
recommendations of the manufacturer.
Cell-Free Translation/Translocation Assays. In vitro tran-
scription, translation, and translocation assays were done as previously
described.14,30 The indicated genes were transcribed with T7 or SP6
polymerase, translated at 32 °C in the presence of microsomes, 35S-
Met, and indicated inhibitors. The translocation was confirmed either
with endoglycosidase (EndoH) treatment or protease protection assay
with proteinase K (PK). All the samples were TCA-precipitated
before gel analysis. The synthesized proteins were detected by SDS-
PAGE and autoradiography.
Photoaffinity Labeling. The photoaffinity labeling and click
chemistry with microsomes were done as previously described.17
Sheep rough microsomes (SRMs) containing 100 nM Sec61 were first
incubated for 30 min with indicated inhibitors, then with 100 nM
photocoibamide or photocotransin CT7 for 10 min and cross-linking
performed by UV-irradiation for 10 min. After denaturation with SDS,
copper catalyzed Click chemistry was used to label the cross-linked
adducts with the fluorescent group. The labeled proteins were
analyzed by SDS-PAGE and in-gel fluorescence. For in cell photo-
cross-linking, 1.5 × 105 A431 cells were plated into each well on a 12-
well plate and grown for 24 h. After washing the cells twice with
Dulbecco’s PBS, media containing either the competing, unlabeled
CbA, or vehicle (0.1% DMSO) were added. The cells were incubated
in the cell incubator for 1 h, photo-CbA added, and the incubation
continued for 30 min. The wells were washed twice with Dulbecco’s
PBS and photolyzed with UV irradiation (50 W, 365 nm) for 10 min.
Cells were collected by scraping, pelleted, and resuspended into 50
mM HEPES, pH 7.5, 100 mM KOAc, 250 mM sucrose, 2 mM
Mg(OAc)2, 1% Triton X-100, and protease inhibitor (Pierce Protease
Inhibitor, EDTA-free). The lysed cells were centrifuged at 21 100g for
10 min, the supernatant collected, and the proteins denatured by
adding 1.1% SDS. The click chemistry and gel analysis were done as
with the reactions containing SRMs.
Cell Culture and Cell Viability Assays, Pulse-Labeling of
Cells. A431, HEK293T, and HEK293FRT cells were cultured in
DMEM supplemented with 10% FBS. HCT-116 cells were cultured in
McCoy’s 5A media supplemented with 10% FBS. U87-MG cells were
cultured in Minimum Essential Media (MEM) with 10% FBS, L-
glutamine (2 mM), and 1% penicillin and streptomycin. MDA-MB-
231 cells were cultured in MEM with Earl’s salts plus 1% penicillin/
streptomycin and 10% FBS. All cell lines were incubated at 37 °C
under 5% CO2. The activity of synthetic coibamide and photoaffinity
analogues was tested in MDA-MB-231 and A549 cells after 72 h by
MTS assay. All other cell viability assays were performed by seeding
PerkinElmer Viewplate-96 plates at a density of 2.5 × 103 cells per
well. Cells were allowed 24 h to adhere and then treated with
indicated concentrations of inhibitors or vehicle (0.1% DMSO) for a
further 72 h. Viability was estimated by the addition of Alamar Blue
(Life Technologies) and measuring fluorescence after a further 4 h.
Pulse-labeling experiments were performed by seeding six-well plates
with 5 × 105 cells per well and allowing 24 h for cells to adhere. Cells
were washed twice with PBS, then exchanged into Met-Cys free media
with indicated concentrations of inhibitors for 30 min. 100 μCi of
PerkinElmer EXPRE35S35S Protein Labeling Mix was then added per
well. Media wer collected, and the cells were harvested by scraping
them into ice cold PBS after 30 min. Total protein was acquired by
RIPA extraction from the cell pellet. Glycosylated protein was
acquired by Concanavalin A purification, and secreted protein was
acquired by TCA precipitation of the media.
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Cellular Thermal Shift Assay. Assays were carried out according
to a method previously described by Jafari and co-workers.44 Briefly, a
melting curve for Sec61α was established in U87-MG glioblastoma
cells. Whole cells were treated as indicated for 1 h, harvested using
trypsin, and collected by gentle centrifugation at 300g for 3 min. Cell
pellets were resuspended in PBS supplemented with PMSF and
benzamidine to a final cell density of ∼2 × 106 cells/mL. The
resulting cell suspension was equally distributed into PCR tubes and
subjected to a range of temperatures (45 to 72 °C) using a Veriti 96-
well thermal cycler. Cells were heated to the designated temperature
for 3 min and immediately snap-frozen in liquid nitrogen. All samples
were subjected to two freeze−thaw cycles. Lysates were cleared by
centrifugation at 18,000g for 20 min, at 4 °C, and the supernatants
were carefully transferred to new tubes for immunoblot analysis. For
isothermal concentration−response fingerprinting of Sec61α, U87-
MG cells were harvested, as above, and resuspended in fresh medium
to a cell density of ∼4 × 107 cells/mL. CbA, OSU-03012, or DMSO
(final 0.1%) in 50 μL of cell medium was added to 15 μL of the cell
suspension and incubated at 37 °C for 30 min. Cells were then
subjected to a 51 °C heat treatment in a Veriti 96-well thermal cycler
for 3 min and immediately snap-frozen in liquid nitrogen. The
samples went through two freeze−thaw cycles, centrifugation, and
preparation for immunoblot analysis as described above.
Resistant Cell Line Isolation. For obtaining resistant cell lines,
HCT-116 cells were mutagenized by incubation with ethyl-
methanesulfonate (EMS) at a concentration of 2000 μg/mL for 60
min. Cells were allowed 48 h to recover, then cultured in the presence
of 50−100 nM coibamide A for 14 days, after which cell colonies were
isolated by disc cloning and cultured further in drug-free media. Total
RNA was isolated using Trizol reagent according to the
manufacturer’s instructions. Total cDNA was synthesized using
anchored oligo(dT) primers and SuperScript IV reverse transcriptase
(Invitrogen). Different cDNAs were amplified with Phusion polymer-
ase (Thermo Fisher Scientific) and sequenced bidirectionally by
Sanger sequencing.
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